EMERYVILLE, CA (August 14, 2007) -- Omicia, Inc., a privately held company specializing in personalized genetic signatures for early detection of disease risk, has been awarded its fourth NIH grant, a $182,732 Small Business Technology Transfer (STTR) Phase I grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health. This industry/academia collaboration between Omicia and Johns Hopkins University (JHU) will be headed by Principal Investigator Dr. Joel Bader, an Assistant Professor of Biomedical Engineering at JHU. Drawing upon Omicias advanced understanding of disease genes and phenotypes and Dr. Baders expertise in gene interaction networks and model organism genetics, the project will identify genes whose variants increase the risk of developing cardiovascular disease.
